Works matching IS 2509-4254 AND VI 9 AND IP 1 AND DT 2025
Results: 14
Cost-Effectiveness of Three Different New-Generation Drug-Eluting Stents in the Randomised BIO-RESORT Trial at 3 Years: Cost-Effectiveness of Three DES: E. H. Ploumen et al.
- Published in:
- PharmacoEconomics - Open, 2025, v. 9, n. 1, p. 137, doi. 10.1007/s41669-024-00539-x
- By:
- Publication type:
- Article
Acknowledgement to Referees: Acknowledgement to Referees.
- Published in:
- PharmacoEconomics - Open, 2025, v. 9, n. 1, p. 1, doi. 10.1007/s41669-024-00546-y
- Publication type:
- Article
Health Economic Evaluation of Antimicrobial Stewardship, Procalcitonin Testing, and Rapid Blood Culture Identification in Sepsis Care: A 90-Day Model-Based, Cost-Utility Analysis: Sepsis Care Economic Analysis: Wendy I. Sligl et al.
- Published in:
- PharmacoEconomics - Open, 2025, v. 9, n. 1, p. 15, doi. 10.1007/s41669-024-00538-y
- By:
- Publication type:
- Article
Digital Versus Paper-Based Consent from the UK NHS Perspective: A Micro-costing Analysis: Cost of Digital Versus Paper-Based Consent in the UK NHS: R. Houten et al.
- Published in:
- PharmacoEconomics - Open, 2025, v. 9, n. 1, p. 27, doi. 10.1007/s41669-024-00536-0
- By:
- Publication type:
- Article
Integrating Multi-Cancer Early Detection (MCED) Tests with Standard Cancer Screening: System Dynamics Model Development and Feasibility Testing: System Dynamics Modelling for Integrating MCED Tests with Standard Screening: M. Fagery et al.
- Published in:
- PharmacoEconomics - Open, 2025, v. 9, n. 1, p. 147, doi. 10.1007/s41669-024-00533-3
- By:
- Publication type:
- Article
Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand: SGLT2i for Thai Diabetes with HF Patients: T. Kongmalai et al.
- Published in:
- PharmacoEconomics - Open, 2025, v. 9, n. 1, p. 69, doi. 10.1007/s41669-024-00526-2
- By:
- Publication type:
- Article
Costs of Illness for Huntington's Disease: A Systematic Review: Review of Costs in HD: D. Patil et al.
- Published in:
- PharmacoEconomics - Open, 2025, v. 9, n. 1, p. 5, doi. 10.1007/s41669-024-00531-5
- By:
- Publication type:
- Article
Costs of Adverse Events in Patients with Advanced or Metastatic Renal Cell Carcinoma with First-Line Treatment: Costs of Adverse Events in aRCC: Y. Chen et al.
- Published in:
- PharmacoEconomics - Open, 2025, v. 9, n. 1, p. 125, doi. 10.1007/s41669-024-00534-2
- By:
- Publication type:
- Article
CMS's Drug Price Negotiation Program 2023 Patient-Focused Listening Sessions: A Descriptive Analysis of Speaker Remarks: Analysis of Speaker Remarks in CMS's 2023 Patient-Focused Listening Sessions: J. A. Patterson et al.
- Published in:
- PharmacoEconomics - Open, 2025, v. 9, n. 1, p. 103, doi. 10.1007/s41669-024-00530-6
- By:
- Publication type:
- Article
Estimation of Health State Utility Values for Immunoglobulin A Nephropathy: A Time Trade-Off Analysis: Time Trade-Off Analysis of Health State Utility Values for IgAN: Z.-Y. Zhou et al.
- Published in:
- PharmacoEconomics - Open, 2025, v. 9, n. 1, p. 83, doi. 10.1007/s41669-024-00527-1
- By:
- Publication type:
- Article
Mortality, Clinical Complications, and Healthcare Resource Utilization Associated with Managing Transfusion-Dependent β-Thalassemia and Sickle Cell Disease with Recurrent Vaso-occlusive Crises in Italy: Burden of TDT and SCD with Recurrent VOCs in Italy: C. Udeze et al
- Published in:
- PharmacoEconomics - Open, 2025, v. 9, n. 1, p. 115, doi. 10.1007/s41669-024-00532-4
- By:
- Publication type:
- Article
Healthcare Resource Utilization and Associated Costs During the First 5 Years After Diagnosis and at the End of Life: A Nationwide Cohort Study of Patients with Multiple Myeloma in Finland: Healthcare Resource Use and Costs of Multiple Myeloma in Finland: M. Kosunen et al
- Published in:
- PharmacoEconomics - Open, 2025, v. 9, n. 1, p. 57, doi. 10.1007/s41669-024-00524-4
- By:
- Publication type:
- Article
Cost-Effectiveness of Fruquintinib for Refractory Metastatic Colorectal Cancer in the USA: Cost-Effectiveness of Fruquintinib in Metastatic Colorectal Cancer: D.-W. Kang et al.
- Published in:
- PharmacoEconomics - Open, 2025, v. 9, n. 1, p. 93, doi. 10.1007/s41669-024-00529-z
- By:
- Publication type:
- Article
Cost Effectiveness of Sequencing Vedolizumab as First-Line Biologic in Ulcerative Colitis and Crohn's Disease in Canada: An Analysis Using Real-World Evidence from the EVOLVE Study: Cost Effectiveness of Vedolizumab as First-Line Biologic in Inflammatory Bowel Diseases: A. Fischer et al
- Published in:
- PharmacoEconomics - Open, 2025, v. 9, n. 1, p. 41, doi. 10.1007/s41669-024-00523-5
- By:
- Publication type:
- Article